Browsing by Author "Ayan, Gizem"

Now showing 1 - 3 of 3

A novel variant in severe disease of dada2: Involving vasculitic and haematologic features
(Taylor & Francis Ltd, 2022-07-18) Ayan, Gizem; Çınar, Olgun Erkin; Çağdaş, Ayvaz Deniz Nazire; Özbek, Deniz Aral; Tuncer, Alaettin; Oğuz, K. K.; Özen, Seza; Alikaşifoğlu, Mehmet; Karadağ, Ömer; Yağiz, Burcu; YAĞIZ, BURCU; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.; JQW-5031-2023
Psart-id inception cohort: Clinical characteristics, treatment choices and outcomes of patients with psoriatic arthritis
(Oxford University, 2021-04-01) Ayan, Gizem; Aydin, Sibel Zehra; Kimyon, Gezmis; Ozisler, Cem; Tinazzi, Ilaria; Dogru, Atalay; Omma, Ahmet; Kilic, Levent; Kucuksahin, Orhan; Gonullu, Emel; Can, Meryem; Ylldlz, Fatih; Solmaz, Dilek; Bayindir, Ozun; Esmen, Serpil Ergulu; Ersozlu, Emine Duygu; Duruoz, Mehmet Tuncay; Akyol, Lutfi; Kucuk, Adem; Bes, Cemal; Erden, Abdulsamet; Bakirci, Sibel; Kasifoglu, Timucin; Kalyoncu, Umut; Balkarli, Aye; Dalkilic, Ediz; Cetin, Gozde Yildirim; Cinar, Muhammet; Mercan, Ridvan; Yazisiz, Veli; Dalkılıç, Ediz; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0003-1889-9619; 0000-0001-7475-3927; 0000-0002-6990-4206; 0000-0003-3628-8870; 0000-0002-9035-689X; 0000-0003-3584-2788; 0000-0001-8028-1671; 0000-0002-8084-2018; 0000-0002-2745-7700; 0000-0001-9680-7535; 0000-0002-6150-3539; GQQ-3193-2022; I-2307-2016; W-2397-2019; K-7985-2019; B-1448-2016; AAK-7851-2021; HLP-4890-2023; GZA-3287-2022; P-2555-2018; C-1808-2016
Objectives. Our aim is to understand clinical characteristics, real-life treatment strategies, outcomes of early PsA patients and determine the differences between the inception and established PsA cohorts.Methods. PsArt-ID (Psoriatic Arthritis- International Database) is a multicentre registry. From that registry, patients with a diagnosis of PsA up to 6 months were classified as the inception cohort (n=388). Two periods were identified for the established cohort: Patients with PsA diagnosis within 5-10 years (n = 328), >= 10 years (n = 326). Demographic, clinical characteristics, treatment strategies, outcomes were determined for the inception cohort and compared with the established cohorts.Results. The mean (S.D.) age of the inception cohort was 44.7 (13.3) and 167/388 (43.0%) of the patients were male. Polyarticular and mono-oligoarticular presentations were comparable in the inception and established cohorts. Axial involvement rate was higher in the cohort of patients with PsA >= 10 years compared with the inception cohort (34.8% vs 27.7%). As well as dactylitis and nail involvement (P = 0.004, P = 0.001 respectively). Both enthesitis, deformity rates were lower in the inception cohort. Overall, 13% of patients in the inception group had a deformity. MTX was the most commonly prescribed treatment for all cohorts with 10.7% of the early PsA patients were given anti-TNF agents after 16 months.Conclusion. The real-life experience in PsA patients showed no significant differences in the disease pattern rates except for the axial involvement. The dactylitis, nail involvement rates had increased significantly after 10 years from the diagnosis and the enthesitis, deformity had an increasing trend over time.
Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study
(Springer London, 2021-08-23) Karadağ, Ömer; Dalkılıç, Ediz; Ayan, Gizem; Küçükşahin, Orhan; Kaşifoğlu, Timuçin; Yılmaz, Neslihan; Koca, Süleyman Serdar; Yazısız, Veli; Erten, Pınar Talu; Sayarlıoğlu, Mehmet; Terzioğlu, Mustafa Ender; Erten, Şükran; Kalyoncu, Umut; DALKILIÇ, HÜSEYİN EDİZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Romatoloji Bilim Dalı.; CMF-4757-2022
Objectives To understand change in work productivity, activity impairment, quality of life (QoL), and disease activity in patients with psoriatic arthritis (PsA) receiving anti-tumor necrosis factor (anti-TNF) treatment.Method One hundred twenty patients with PsA receiving anti-TNF therapy were recruited to this noninterventional, observational study. Work disability was assessed via the Work Productivity and Activity Impairment (WPAI) questionnaire and disease activity was calculated via the 28-joint Disease Activity Score using C-reactive protein (DAS28-CRP) and Disease Activity Index for Psoriatic Arthritis with 28 joints (DAPSA28) score. Patient-reported outcomes (PROs), from visual analog scores and Health Assessment Questionnaire-Disability Index scores, were evaluated to understand the clinical effectiveness at baseline and every 3 months until the month-9 final visit. The American College of Rheumatology (ACR)20/50/70 response criteria were assessed at month 9.Results A total of 120 patients (females, n = 73) were enrolled in the study. Mean (SD) age and disease duration were 41.6 +/- 11.1 years and 6.9 +/- 6.5 years, respectively. The most commonly used TNF alpha inhibitor was adalimumab (42.4%), followed by etanercept (25.8%). All WPAI questionnaire parameters were reduced at the follow-up visits compared with baseline (p < 0.001 for all). PROs and disease activity indicators (DAS28-CRP and DAPSA28) significantly improved during the course of anti-TNF treatments (p < 0.001 for all). Additionally, ACR20/50/70 responses were determined as 86.8%, 63.7%, and 41.8% of patients at the month-9 visit.Conclusions The real-world data in PsA patients receiving anti-TNF treatment showed improvement in WPAI, QoL, and disease activity over 9 months of treatment.